168 related articles for article (PubMed ID: 36578488)
1. Potentiating pneumococcal glycoconjugate vaccine PCV13 with saponin adjuvant VSA-1.
Kim H; Yu J; Bai D; Nahm MH; Wang P
Front Immunol; 2022; 13():1079047. PubMed ID: 36578488
[TBL] [Abstract][Full Text] [Related]
2. Structure-Activity Relationship Study of
Kim H; Bai D; Ghosh S; Franks ML; Wang X; Yan C; Liu Z; Zhang P; Michalek SM; Leavenworth JW; Wang P
J Med Chem; 2022 Nov; 65(21):14589-14598. PubMed ID: 36318612
[TBL] [Abstract][Full Text] [Related]
3. Structural Effect on Adjuvanticity of Saponins.
Wang P; Ding X; Kim H; Michalek SM; Zhang P
J Med Chem; 2020 Mar; 63(6):3290-3297. PubMed ID: 32101001
[TBL] [Abstract][Full Text] [Related]
4. Vaccine Adjuvants Derivatized from
Wang P; Ding X; Kim H; Škalamera Đ; Michalek SM; Zhang P
J Med Chem; 2019 Nov; 62(21):9976-9982. PubMed ID: 31657920
[TBL] [Abstract][Full Text] [Related]
5. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine.
Wu JY; Gardner BH; Murphy CI; Seals JR; Kensil CR; Recchia J; Beltz GA; Newman GW; Newman MJ
J Immunol; 1992 Mar; 148(5):1519-25. PubMed ID: 1538134
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Evaluation of a QS-17/18-Based Vaccine Adjuvant.
Wang P; Škalamera Đ; Sui X; Zhang P; Michalek SM
J Med Chem; 2019 Feb; 62(3):1669-1676. PubMed ID: 30656932
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol.
Fernández-Tejada A; Chea EK; George C; Gardner JR; Livingston PO; Ragupathi G; Tan DS; Gin DY
Bioorg Med Chem; 2014 Nov; 22(21):5917-23. PubMed ID: 25284254
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant Effects of a New Saponin Analog VSA-1 on Enhancing Homologous and Heterosubtypic Protection by Influenza Virus Vaccination.
Bhatnagar N; Kim KH; Subbiah J; Park BR; Wang P; Gill HS; Wang BZ; Kang SM
Vaccines (Basel); 2022 Aug; 10(9):. PubMed ID: 36146461
[TBL] [Abstract][Full Text] [Related]
9. Novel Oxime-Derivatized Synthetic Triterpene Glycosides as Potent Saponin Vaccine Adjuvants.
Fuentes R; Aguinagalde L; Pifferi C; Plata A; Sacristán N; Castellana D; Anguita J; Fernández-Tejada A
Front Immunol; 2022; 13():865507. PubMed ID: 35603193
[TBL] [Abstract][Full Text] [Related]
10. Development of Improved Vaccine Adjuvants Based on the Saponin Natural Product QS-21 through Chemical Synthesis.
Fernández-Tejada A; Tan DS; Gin DY
Acc Chem Res; 2016 Sep; 49(9):1741-56. PubMed ID: 27568877
[TBL] [Abstract][Full Text] [Related]
11. Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants.
Marty-Roix R; Vladimer GI; Pouliot K; Weng D; Buglione-Corbett R; West K; MacMicking JD; Chee JD; Wang S; Lu S; Lien E
J Biol Chem; 2016 Jan; 291(3):1123-36. PubMed ID: 26555265
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to korean children receiving routine pediatric vaccines.
Kim DS; Shin SH; Lee HJ; Hong YJ; Lee SY; Choi KM; Oh CE; Kim KH; Juergens C; Patterson S; Giardina PC; Gruber WC; Emini EA; Scott DA
Pediatr Infect Dis J; 2013 Mar; 32(3):266-73. PubMed ID: 23011012
[TBL] [Abstract][Full Text] [Related]
13. Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children.
Sigurdardottir ST; Center KJ; Davidsdottir K; Arason VA; Hjalmarsson B; Elisdottir R; Ingolfsdottir G; Northington R; Scott DA; Jonsdottir I
Vaccine; 2014 Jan; 32(3):417-24. PubMed ID: 24300594
[TBL] [Abstract][Full Text] [Related]
14. Potent response of QS-21 as a vaccine adjuvant in the skin when delivered with the Nanopatch, resulted in adjuvant dose sparing.
Ng HI; Fernando GJ; Depelsenaire AC; Kendall MA
Sci Rep; 2016 Jul; 6():29368. PubMed ID: 27404789
[TBL] [Abstract][Full Text] [Related]
15. Platycodin D is a potent adjuvant of specific cellular and humoral immune responses against recombinant hepatitis B antigen.
Xie Y; Sun HX; Li D
Vaccine; 2009 Jan; 27(5):757-64. PubMed ID: 19041358
[TBL] [Abstract][Full Text] [Related]
16. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
Svensson T; Kättström M; Hammarlund Y; Roth D; Andersson PO; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
Vaccine; 2018 Jun; 36(25):3701-3707. PubMed ID: 29748028
[TBL] [Abstract][Full Text] [Related]
17. Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule.
Rodgers GL; Esposito S; Principi N; Gutierrez-Brito M; Diez-Domingo J; Pollard AJ; Snape MD; Martinón-Torres F; Gruber WC; Patterson S; Thompson A; Gurtman A; Paradiso P; Scott DA
Vaccine; 2013 Oct; 31(42):4765-74. PubMed ID: 23965217
[TBL] [Abstract][Full Text] [Related]
18. Immunological adjuvant activities of saponin extracts from the pods of Acacia concinna.
Kukhetpitakwong R; Hahnvajanawong C; Homchampa P; Leelavatcharamas V; Satra J; Khunkitti W
Int Immunopharmacol; 2006 Nov; 6(11):1729-35. PubMed ID: 16979128
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.
Esposito S; Tansey S; Thompson A; Razmpour A; Liang J; Jones TR; Ferrera G; Maida A; Bona G; Sabatini C; Pugni L; Emini EA; Gruber WC; Scott DA; Principi N
Clin Vaccine Immunol; 2010 Jun; 17(6):1017-26. PubMed ID: 20427630
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Compared With 7-valent Pneumococcal Conjugate Vaccine Among Healthy Infants in China.
Zhu F; Hu Y; Li J; Ye Q; Young MM; Zhou X; Chen Z; Yan B; Liang JZ; Gruber WC; Giardina PC; Scott DA
Pediatr Infect Dis J; 2016 Sep; 35(9):999-1010. PubMed ID: 27254028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
